Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial

There is an unmet need for therapeutic options that prolong survival for patients with heavily pretreated, metastatic castration-resistant prostate cancer (mCRPC). The phase III, open-label KEYLYNK-010 study evaluated pembrolizumab plus olaparib versus a next-generation hormonal agent (NHA) for biom...

Descripción completa

Detalles Bibliográficos
Autores principales: Antonarakis, Emmanuel S., Park, Se Hoon, Goh, Jeffrey C., Shin, Sang Joon, Lee, Jae Lyun, Mehra, Niven, McDermott, Ray, Sala-Gonzalez, Núria, Fong, Peter C., Greil, Richard, Retz, Margitta, Sade, Juan Pablo, Yanez, Patricio, Huang, Yi-Hsiu, Begbie, Stephen D., Gafanov, Rustem Airatovich, De Santis, Maria, Rosenbaum, Eli, Kolinsky, Michael P., Rey, Felipe, Chiu, Kun-Yuan, Roubaud, Guilhem, Kramer, Gero, Sumitomo, Makoto, Massari, Francesco, Suzuki, Hiroyoshi, Qiu, Ping, Zhang, Jinchun, Kim, Jeri, Poehlein, Christian H., Yu, Evan Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419579/
https://www.ncbi.nlm.nih.gov/pubmed/37290035
http://dx.doi.org/10.1200/JCO.23.00233

Ejemplares similares

Ejemplares similares